CSRA (NYSE: CSRA) and MedAssets (NASDAQ:MDAS) are both technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings & Valuation

This table compares CSRA and MedAssets’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CSRA $4.99 billion 1.00 $304.00 million $1.92 15.87
MedAssets N/A N/A N/A ($0.59) -53.14

CSRA has higher revenue and earnings than MedAssets. MedAssets is trading at a lower price-to-earnings ratio than CSRA, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

94.7% of CSRA shares are owned by institutional investors. 0.4% of CSRA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares CSRA and MedAssets’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CSRA 6.35% 79.44% 6.35%
MedAssets -1.18% -2.00% -0.54%

Analyst Ratings

This is a summary of current recommendations for CSRA and MedAssets, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CSRA 1 2 6 0 2.56
MedAssets 0 0 0 0 N/A

CSRA currently has a consensus target price of $36.44, indicating a potential upside of 19.61%. Given CSRA’s higher possible upside, equities analysts clearly believe CSRA is more favorable than MedAssets.

Dividends

CSRA pays an annual dividend of $0.40 per share and has a dividend yield of 1.3%. MedAssets does not pay a dividend. CSRA pays out 20.8% of its earnings in the form of a dividend.

Summary

CSRA beats MedAssets on 11 of the 12 factors compared between the two stocks.

About CSRA

CSRA Inc. is a provider of information technology services to the United States federal government. The Company operates through two segments: Defense and Intelligence, and Civil. The Defense and Intelligence segment provides services to the Department of Defense (DoD), National Security Agency, branches of the Armed Forces, and other DoD and Intelligence agencies. The Civil segment provides services to various federal agencies within the Department of Homeland Security (the DHS), Department of Health and Human services, and other federal civil agencies, as well as various state and local government agencies. It supplies civil government agencies with mission information systems and associated technical support services. It provides its customers with technical services across service areas, including Digital Services, Enterprise Business Services, Digital Platforms, Cyber, Data Science, and Professional and Citizen Services. It has conducted operations in over 130 locations.

About MedAssets

MedAssets, Inc. (MedAssets) provides technology-enabled products and services to healthcare organizations, including hospitals, health systems, non-acute healthcare providers, payers, other service providers and product manufacturers. The Company operates its business through two business segments: Spend and Clinical Resource Management (SCM) and Revenue Cycle Management (RCM). The SCM segment delivers market insight, performance improvement advisory and cost management capabilities to healthcare providers. The RCM segment provides revenue cycle management solutions to healthcare providers, primarily hospitals and health systems. The Company’s technology-enabled solutions are delivered through the Company-hosted software or software as a service (SaaS) or Web-based applications. Its Web-based applications employ cloud computing by using the Internet to deploy the Company’s solutions across decentralized health care organizations, providing standardization and compliance.

Receive News & Ratings for CSRA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSRA and related companies with MarketBeat.com's FREE daily email newsletter.